Breaking News $RXSF @RxDrugSAFE – #RXSafes Announces New Additions to Executive Team

Breaking News $RXSF @RxDrugSAFE – #RXSafes Announces New Additions to Executive Team


NOTE: This company now trades as GeneSYS ID, Inc. (OTCQB: GNID).



RX Safes Announces New Additions to Executive Team

Company Expands Sales and Marketing With Proven Results-Driven Executives

HENDERSON, NV — (Marketwired) — 02/02/16 — Rx Safes, Inc. (OTCQB: RXSF), a healthcare technology company and developer of autonomous fingerprint healthcare security products, today announced the expansion of the Company’s executive team with the appointment of William V. Koch as Chief Sales and Marketing Officer and Faruk Okcetin as Vice President of Professional Sales.

William V. Koch has a long history of developing sales and marketing programs for Pitney Bowes and The Tweddle Group, where he was directly credited for sales growth exceeding $135M annually. As the newly appointed Chief Sales and Marketing Officer, Mr. Koch will work to strengthen the position of the Company’s technology and products as well as expand the Company’s sales and marketing initiatives in a multi-billion dollar healthcare market opportunity.

Faruk Okcetin is a seasoned medical device and equipment sales executive, and a founding partner at Aspire Medical Services. At Aspire, he was responsible for selling a multi-million dollar surgical implant and instrumentation line across multiple healthcare systems, including Novant Health and CMC Mercy Hospitals. Mr. Okcetin’s experience includes working directly with hospital decision makers, physicians and managing sales personnel.

“Building an experienced sales and marketing executive team was a critical component of the Company’s growth initiatives. We are fortunate to have existing board members join our executive team who share our vision for the application of biometric technology in an underserved market. I believe we are uniquely positioned to use our technology to help healthcare organizations address the direct costs and potential liabilities associated with drug diversion and abuse,” commented Lorraine Yarde, Rx Safes’ Chief Executive Officer. “These two appointments follow the appointment of Mark Basile, a co-founder of Rx Safes, Inc. as Chief Strategy Officer, and further strengthen the Company’s management team.”

About Rx Safes, Inc.

Rx Safes is medical device and healthcare technology company, and is an emerging leader in the personal and professional healthcare drug security market. Our products incorporate proprietary patented fingerprint technology to provide drug security solutions for use in homes and healthcare facilities. Prescription drug misuse, skyrocketing insurance and pharmaceutical treatment costs and increased regulatory pressures create an unfortunate, yet necessary opportunity for Rx Safes to expand our reach and offerings in this growing market, valued at over $50 billion annually. Annual spending on healthcare technology products exceeds $34.5 billion. In addition, the market is being driven by ongoing Government support for successful drug abuse prevention initiatives, with a financial commitment of $25.4 billion in 2015 alone. For more information, please visit

Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management’s current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the successful execution of the Company’s business strategy. The Company’s actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Such risks and uncertainties include, among other things, our ability to establish and maintain the proprietary nature of our technology through the patent process, as well as our ability to possibly license from others patents and patent applications necessary to develop products; the availability of financing; the Company’s ability to implement its long range business plan for various applications of its technology; the Company’s ability to enter into agreements with any necessary marketing and/or distribution partners; the impact of competition, the obtaining and maintenance of any necessary regulatory clearances applicable to applications of the Company’s technology; and management of growth and other risks and uncertainties that may be detailed from time to time in the Company’s reports filed with the Securities and Exchange Commission.

Like us on Facebook at
Follow us on Twitter at

Keywords: JPM16, SOTU, Carly Fiorina, Jeb Bush, Donald Trump, Chris Christie, Bernie Sanders, President Obama, JP Morgan Healthcare Conference, Drugs, prescription drug abuse, medicine, drug diversion, healthcare, overdose, addiction, fingerprint, biometric, safe, security, technology, government, lockbox, McKesson, Cardinal Health, CVS, Walgreens, hospital, health system, medical equipment, FDA, CDC, DEA, methadone, oxycontin, lortab, hydroconone, zohydro, Zogenix, Purdue, King Pharmaceutical, heroin, doctor, pharmacist, biometric, marijuana, weed, painkillers, clinics, sober house, rehabilitation, OTC, patients, health network, nurses, clinicians, labs, smuggle, drug money, oxy, abuse, speed, crack, cocaine, pills, roofies, qualudes, prozac, morphine, ambulance, EMS, paramedics, ecstasy, LSD, high, stoned, drugged, pharmaceutical, pharmacy, narcotics, non-profit, not-for-profit, nonprofit, foundation, padlock, Master Lock

Logo Header Menu